Track: Cardiometabolic Disease, Lipidology, and Atherosclerosis
The global epidemics of obesity, type 2 diabetes, and metabolic syndrome are driving a parallel surge in cardiovascular disease burden. The Cardiometabolic Syndrome, Obesity & Diabetes in Cardiology session examines the transformative cardiovascular outcomes data for GLP-1 receptor agonists including the LEADER, SUSTAIN-6, and SELECT trials establishing mortality benefits in diabetic and non-diabetic cardiovascular risk cohorts - SGLT2 inhibitor cardiorenal benefits in diabetic and non-diabetic heart failure, emerging dual GIP/GLP-1 agonists (tirzepatide) in cardiovascular outcomes, visceral adiposity as an imaging-based cardiovascular risk marker, non-alcoholic fatty liver disease (MASLD) as an emerging cardiovascular risk factor, and the cardiometabolic consequences of weight cycling.
Key Discussion Areas:
- GLP-1 receptor agonists: cardiovascular outcomes across SELECT, LEADER, and SUSTAIN-6
- SGLT2 inhibitors in diabetic and non-diabetic HFrEF and HFpEF
- Tirzepatide and dual GIP/GLP-1 agonists: emerging cardiovascular outcomes data
- Visceral adiposity and pericardial fat as imaging-based cardiovascular risk markers
- MASLD/MASH and cardiovascular risk: emerging evidence and management
- Insulin resistance and cardiovascular disease: pathophysiological mechanisms
- Bariatric and metabolic surgery: cardiovascular outcomes and risk reduction
- Polycystic ovary syndrome (PCOS) and early cardiovascular risk in women
Why Attend This Session?
Cardiologists, endocrinologists, diabetologists, preventive medicine specialists, and primary care physicians will benefit from an integrated update on the cardiovascular benefits of cardiometabolic therapies, risk stratification tools, and multidisciplinary management strategies for the growing intersection of metabolic and cardiovascular disease.
Related Topics:
Preventive Cardiology & Cardiovascular Risk Reduction
Heart Failure & Cardiomyopathies
Hypertension & Hypertensive Heart Disease
Women's Heart Health
Cardiac Imaging & Advanced Diagnostics
Frequently Asked Questions:
1.What is the importance of cardiometabolic disease, lipidology, and atherosclerosis in cardiovascular medicine?
Cardiometabolic Disease, Lipidology, and Atherosclerosis plays a significant role in improving diagnosis, treatment strategies, patient outcomes, and clinical decision-making in modern cardiology.
2.What are the latest trends in cardiometabolic disease, lipidology, and atherosclerosis?
Recent trends include precision medicine, AI-assisted diagnostics, minimally invasive therapies, digital healthcare technologies, and personalized patient management.
Scientific Highlights
- Preventive Cardiology and Cardiovascular Risk Reduction
- Heart Failure and Advanced Cardiac Therapies
- Interventional Cardiology and Structural Heart Disease
- Cardiac Electrophysiology and Arrhythmia Management
- Acute Coronary Syndromes
- Cardiovascular Imaging and Multimodality Diagnostics
- Cardiomyopathies: Genetics, Phenotyping, and Treatment
- Cardio Oncology
- Cardiometabolic Disease, Lipidology, and Atherosclerosis
- Hypertension and Renal Cardiovascular Interactions
- Digital Health, AI, and the Future of Cardiology
- Pediatric and Congenital Cardiology
- Vascular Medicine and Aortic Diseases
- Women's Cardiovascular Health and Sports Cardiology
- Precision Medicine, Genomics, and Regenerative Cardiology
- Cardiovascular and Cardiothoracic Surgery
- Cardiovascular Case Studies and Clinical Insights
- Emergency and Critical Cardiac Care
Organization Location
1309 Coffeen Avenue, STE 1200, Sheridan, Wyoming 82801, USA
Mail us at
Conference Enquiry - Kristina Pierce
kristinapierce@scientexconferences.com
General Enquiry
contact@scientexconferences.com
Registration Enquiry
finance@scientexconferences.com
cardiacsurgery@scientexevents.org
Our Social Presence
Call us at
USA : (+1) 272 374 1068